Grant: Doctoral Research Award: Canada Graduate Scholarships
McMaster University
$105,000.00
Exploring novel combinatorial therapies for personalized management of Cystic Fibrosis using primary human airway epithelial cells
FY 2020-21
Summary
Cystic Fibrosis is the most common genetic condition affecting Canadian newborns (1 in 3600), and is caused by the inheritance of a mutation, from each parent, in the gene for the Cystic Fibrosis transmembrane conductance regulator. People with Cystic Fibrosis, due to their mutations, experience several problems with their lungs including shortness of breath, increased mucus production, and susceptibility to infections. Collectively, these problems can lead to damage of the lungs and early death. There have been great strides in the development of drugs that can treat many patients that have Cystic Fibrosis, with combinations of several drugs more effective than a single drug. However, some Cystic Fibrosis patients remain unresponsive to existing drug combinations and continue to experience symptoms and damage to their lungs. It is therefore important to find new combinations of drugs that can improve the quality of life for all Cystic Fibrosis patients. In this project, I investigate the effectiveness of new drugs, which can be added on top of existing drugs, that target proteins that interact with the Cystic Fibrosis transmembrane conductance regulator. This study will use human airway epithelial cells from Cystic Fibrosis patient donors covering a diverse range of the Cystic Fibrosis population. These drugs will be given in combination with currently approved drugs to cells from Cystic Fibrosis patients and we aim to identify potential Cystic Fibrosis patient populations that will benefit from our novel treatment strategy. Our research provides an alternative and complementary strategy to increase the function of the Cystic Fibrosis transmembrane conductance regulator. This has the potential to help all Canadians living with Cystic Fibrosis and may reveal distinct populations that may benefit from our proposed drug combination. In addition, this will provide a rationale for the development of new drugs for personalized therapy in Cystic Fibrosis.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
439577
Name
Nguyen Jenny P
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Exploring novel combinatorial therapies for personalized management of Cystic Fibrosis using primary human airway epithelial cells
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Cell Biology; Cell Culture; Cystic Fibrosis; Diagnostics; Drug Discovery - Correctors; Drug Discovery - Potentiators; Fluorescent Plate-Based Assays; Predictors; Primary Cells
Abstract
Cystic Fibrosis is the most common genetic condition affecting Canadian newborns (1 in 3600), and is caused by the inheritance of a mutation, from each parent, in the gene for the Cystic Fibrosis transmembrane conductance regulator. People with Cystic Fibrosis, due to their mutations, experience several problems with their lungs including shortness of breath, increased mucus production, and susceptibility to infections. Collectively, these problems can lead to damage of the lungs and early death. There have been great strides in the development of drugs that can treat many patients that have Cystic Fibrosis, with combinations of several drugs more effective than a single drug. However, some Cystic Fibrosis patients remain unresponsive to existing drug combinations and continue to experience symptoms and damage to their lungs. It is therefore important to find new combinations of drugs that can improve the quality of life for all Cystic Fibrosis patients. In this project, I investigate the effectiveness of new drugs, which can be added on top of existing drugs, that target proteins that interact with the Cystic Fibrosis transmembrane conductance regulator. This study will use human airway epithelial cells from Cystic Fibrosis patient donors covering a diverse range of the Cystic Fibrosis population. These drugs will be given in combination with currently approved drugs to cells from Cystic Fibrosis patients and we aim to identify potential Cystic Fibrosis patient populations that will benefit from our novel treatment strategy. Our research provides an alternative and complementary strategy to increase the function of the Cystic Fibrosis transmembrane conductance regulator. This has the potential to help all Canadians living with Cystic Fibrosis and may reveal distinct populations that may benefit from our proposed drug combination. In addition, this will provide a rationale for the development of new drugs for personalized therapy in Cystic Fibrosis.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Nguyen, Jenny P
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~